CD36 is a co-receptor for hepatitis C virus E1 protein attachment

Lipids and lipid binding proteins: A perfect match

(2015) Jan F.C. Glatz   PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Host APOBEC3G Protein Inhibits HCV Replication through Direct Binding at NS3

(2015) Yan-Ping Zhu et al.   PLoS One

Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1

(2014) Ronald L. Koretz   ANNALS OF INTERNAL MEDICINE

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

(2014) Eric F. Donaldson et al.   HEPATOLOGY

Virology and cell biology of the hepatitis C virus life cycle – An update

(2014) Jean Dubuisson et al.   JOURNAL OF HEPATOLOGY

Targets for Antiviral Therapy of Hepatitis C

(2014) Daniel Rupp et al.   SEMINARS IN LIVER DISEASE

CD81-Receptor Associations — Impact for Hepatitis C Virus Entry and Antiviral Therapies

(2014) Laetitia Zona et al.   Viruses-Basel

Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry

(2013) Liang-Tzung Lin et al.   BMC MICROBIOLOGY

Sulfo-N-succinimidyl Oleate (SSO) Inhibits Fatty Acid Uptake and Signaling for Intracellular Calcium via Binding CD36 Lysine 164

(2013) Ondrej Kuda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

(2013) Marcus Dorner et al.   NATURE

The ins and outs of hepatitis C virus entry and assembly

(2013) Brett D. Lindenbach et al.   NATURE REVIEWS MICROBIOLOGY

Identification of transferrin receptor 1 as a hepatitis C virus entry factor

(2013) D. N. Martin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease

(2013) Takashi Himoto et al.   Diabetology & Metabolic Syndrome

CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke

(2012) Sunghee Cho   CURRENT PHARMACEUTICAL DESIGN

Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding

(2012) Shufeng Liu et al.   HEPATOLOGY

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C

(2012) S. Petta et al.   JOURNAL OF VIRAL HEPATITIS

Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor

(2012) Bruno Sainz et al.   NATURE MEDICINE

CD36 Inhibitors Reduce Postprandial Hypertriglyceridemia and Protect against Diabetic Dyslipidemia and Atherosclerosis

(2012) Alain Geloen et al.   PLoS One

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

(2012) Stefania Paolucci et al.   Virology Journal

Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance

(2011) Yu-Ping Wang et al.   ANTIVIRAL RESEARCH

Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry

(2011) Keisuke Hikosaka et al.   BIOMEDICAL RESEARCH-TOKYO

Synthesis and structure–activity relationship of N-(2-arylethyl) isoquinoline derivatives as human scavenger receptor CD36 antagonists

(2011) Yan-Xiang Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C

(2011) M. E. Miquilena-Colina et al.   GUT

Host apolipoprotein b messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus

(2011) Zong-Gen Peng et al.   HEPATOLOGY

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle

(2011) Anna Albecka et al.   HEPATOLOGY

Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population

(2011) A. Handberg et al.   JOURNAL OF INTERNAL MEDICINE

Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation

(2011) Christine V Ichim et al.   Journal of Translational Medicine

A genetically humanized mouse model for hepatitis C virus infection

(2011) Marcus Dorner et al.   NATURE

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

(2011) Joachim Lupberger et al.   NATURE MEDICINE

Chronic Hepatitis C Infection

(2011) Hugo R. Rosen   NEW ENGLAND JOURNAL OF MEDICINE

CD36 as a lipid sensor

(2011) Céline Martin et al.   PHYSIOLOGY & BEHAVIOR

Gene Expression in Livers of BALB/C and C57BL/6J Mice Fed a High-Fat Diet

(2011) Satomi Nishikawa et al.   TOXICOLOGIC PATHOLOGY

Regulation of Platelet Function by Class B Scavenger Receptors in Hyperlipidemia

(2010) Alejandro Zimman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA

(2010) Zong-Gen Peng et al.   HEPATOLOGY

Tupaia CD81, SR-BI, Claudin-1, and Occludin Support Hepatitis C Virus Infection

(2010) Y. Tong et al.   JOURNAL OF VIROLOGY

The SR-BI Partner PDZK1 Facilitates Hepatitis C Virus Entry

(2010) Nicholas S. Eyre et al.   PLoS Pathogens

Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants

(2009) M. T. Catanese et al.   JOURNAL OF VIROLOGY

Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

(2009) Alexander Ploss et al.   NATURE

CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior

(2009) R. L. Silverstein et al.   Science Signaling

Tight Junction Proteins Claudin-1 and Occludin Control Hepatitis C Virus Entry and Are Downregulated during Infection To Prevent Superinfection

(2008) S. Liu et al.   JOURNAL OF VIROLOGY